Pueraria tuberosa

Pueraria tuberosa contains isoflavones like puerarin and genistein that modulate estrogen receptors and glucose metabolism pathways. Research primarily focuses on its potential lactogenic effects and blood sugar management properties.

Origin & History

Pueraria tuberosa is a tuberous plant native to the Indian subcontinent, belonging to the Fabaceae family. The medicinal preparations are derived from underground tubers through aqueous or ethanolic extraction methods, yielding compounds including alkaloids, flavonoids, and steroidal saponins.

Historical & Cultural Context

Pueraria tuberosa has been used traditionally in Ayurvedic medicine as a spermatogenic agent, immune booster, and aphrodisiac. The plant has also been investigated for traditional contraceptive applications in various animal models.

Health Benefits

• May enhance lactation by increasing prolactin levels (shown in animal studies only - no human trials)
• Potentially protects against diabetic kidney disease by reducing blood glucose and kidney damage markers (preclinical evidence only)
• Demonstrates anti-inflammatory effects through reduction of lipid peroxidation and C-reactive protein (rat model studies)
• Shows anticancer potential against colon cancer cells at 63.91 µg/ml concentration (in vitro evidence only)
• Traditional use as immune booster and reproductive health support (no modern clinical validation)

How It Works

Pueraria tuberosa's isoflavones, particularly puerarin and genistein, bind to estrogen receptors (ERα and ERβ) to stimulate prolactin production in mammary tissues. The compounds also activate AMPK pathways and inhibit α-glucosidase enzymes, improving glucose uptake and reducing blood sugar spikes. Anti-inflammatory effects occur through NF-κB pathway inhibition and cytokine modulation.

Scientific Research

All available evidence comes from preclinical animal models and in vitro studies - no human clinical trials, RCTs, or meta-analyses were identified. Key studies include rat models showing puerarin at 15 mg/kg/day increased milk yield and prolactin levels comparable to domperidone, and PTY-2 fraction reversing diabetic nephropathy markers in streptozotocin-induced diabetic rats.

Clinical Summary

Current evidence for Pueraria tuberosa is limited to animal studies and in vitro research, with no published human clinical trials. Animal studies show 40-60% increases in milk yield and prolactin levels in lactating rats. Preclinical diabetes studies demonstrate 25-35% reductions in blood glucose and improved kidney function markers in diabetic rats. Human efficacy, optimal dosing, and safety profiles remain unestablished due to lack of clinical trials.

Nutritional Profile

Pueraria tuberosa (Indian Kudzu) tuber composition per 100g dry weight: Carbohydrates constitute the dominant macronutrient at approximately 70-75g, primarily as starch and complex polysaccharides. Protein content ranges from 4-6g, containing amino acids including puerarin-associated peptide fractions. Crude fiber is estimated at 3-5g. Fat content is minimal at 0.5-1.5g. Moisture in fresh tubers is approximately 60-70%. Key bioactive isoflavones include puerarin (daidzein-8-C-glucoside) at approximately 1.2-3.5mg/g dry extract, daidzein at 0.8-2.1mg/g, and formononetin at trace to 0.5mg/g — these phytoestrogens are the primary pharmacologically active constituents. Steroidal saponins (tuberosin and related compounds) are present at approximately 0.5-2% of dry weight and are considered responsible for galactagogue and adaptogenic effects. Pueraroside and tuberosin glycosides contribute to antioxidant activity. Mineral content includes moderate potassium (estimated 300-450mg/100g dry), calcium (approximately 80-120mg/100g dry), magnesium (approximately 40-70mg/100g dry), and trace iron and zinc. Vitamin content is limited but includes small amounts of B-complex vitamins. Bioavailability of isoflavones is enhanced by gut microbial conversion; puerarin exhibits relatively high oral bioavailability (~30-40%) compared to other isoflavones. Starch digestibility is moderate. Note: Quantitative data largely derived from phytochemical extraction studies; standardized nutritional analyses on whole tuber are sparse in published literature.

Preparation & Dosage

Animal studies used: Puerarin 15 mg/kg/day, aqueous extract 150 mg/kg/day, or 10-40 mg per 100g body weight for anti-inflammatory effects. No human dosage data available. No standardization markers established. Consult a healthcare provider before starting any new supplement.

Synergy & Pairings

Fenugreek, Blessed Thistle, Shatavari, Ashwagandha, Moringa

Safety & Interactions

Safety data for Pueraria tuberosa in humans is insufficient due to lack of clinical trials. Theoretical concerns include hormonal interactions due to estrogenic isoflavones, particularly in hormone-sensitive conditions like breast or uterine cancer. May interact with diabetes medications by enhancing blood sugar-lowering effects, requiring monitoring. Pregnancy and breastfeeding safety is unknown despite traditional use for lactation support.